Article Text

Download PDFPDF
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
  1. Ignace Vergote, MD, PhD*,
  2. Neil J. Finkler, MD,
  3. James B. Hall, MD,
  4. Ostap Melnyk, MD§,
  5. Robert P. Edwards, MD,
  6. Marsha Jones, MD,
  7. James G. Keck, PhD,
  8. Lisa Meng, MS,
  9. Gail L. Brown, MD,
  10. Elaine M. Rankin, MD#,
  11. James J. Burke, MD**,
  12. Ralph V. Boccia, MD, FACP,,
  13. Carolyn D. Runowicz, MD, and
  14. Peter G. Rose, MD§§
  1. * University Hospitals, Leuven, European Union;
  2. Florida Hospital Cancer Institute, Orlando, FL;
  3. Blumenthal Cancer Center, Charlotte, NC;
  4. § Bay Area Cancer Research Group LLC, Concord, CA;
  5. University of Pittsburgh School of Medicine, Pittsburgh, PA;
  6. Telik, Inc, Palo Alto, CA;
  7. # University of Dundee, Dundee, United Kingdom;
  8. ** Memorial Health University Medical Center, Savannah, GA;
  9. †† Center for Cancer & Blood Disorders, Bethesda, MD;
  10. ‡‡ Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT; and
  11. §§ Cleveland Clinic Foundation, Cleveland, OH.
  1. Address correspondence and reprint requests to Ignace Vergote, MD, PhD, University Hospitals, Leuven, European Union. E-mail: ignace.vergote{at}


Objective: To evaluate the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (OC).

Methods: Patients with platinum-refractory or -resistant (primary or secondary) OC were randomized to receive canfosfamide at 1000 mg/m2 and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Other end points were objective response rate and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.

Results: The median PFS was 5.6 months for canfosfamide + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). A preplanned subgroup analysis showed that 75 patients with platinum-refractory or primary platinum-resistant OC had a median PFS of 5.6 months for canfosfamide + PLD versus 2.9 months for PLD (hazards ratio, 0.55; P = 0.0425). Hematologic adverse events were 66% on the canfosfamide + PLD arm versus 44% on the PLD arm, manageable with dose reductions. Nonhematologic adverse events were similar for both arms. The incidence of palmar-plantar erythrodysesthesia and stomatitis was lower on canfosfamide + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD.

Conclusions: Overall median PFS showed a positive trend but was not statistically significant. The median PFS in the platinum-refractory and primary platinum-resistant OC patients was significantly longer for canfosfamide + PLD versus PLD. Canfosfamide may ameliorate the palmar-plantar erythrodysesthesia and stomatitis known to be associated with PLD. Further study of this active well-tolerated regimen in platinum-refractory and primary platinum-resistant OC is planned.

This study was registered at NCT00350948.

  • Platinum resistant
  • Ovarian cancer
  • Phase 3 clinical trial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.